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Purpose: To report the efficacy of topical interferon alpha 2b in the treatment of
refractory diabetic macular edema.
Methods: In this retrospective interventional case series, five eyes of three individuals
with diabetic macular edema resistant to multiple intravitreal injections of anti-vascular
endothelial growth factor drugs and macular photocoagulation were included.
Results: All studied eyes had undergone multiple intravitreal injections including
bevacizumab, combination of bevacizumab and triamcinolone and aflibercept, and
macular laser photocoagulation before being included in this study. Two intravitreal
ranibizumab injections had also been performed in both eyes of one patient. Two eyes
had undergone pars plana vitrectomy, one for diabetic macular edema and the other
for rhegmatogenous retinal detachment. After a discussion regarding the experimental
topical interferon alpha 2b treatment, all patients agreed to start interferon alpha 2b
drops four times a day. One month after the treatment, optical coherence tomography
demonstrated a significant improvement in macular structure and thickness which was
stable or improved at the three-month follow-up visit. Visual acuity in all eyes was stable
or improved throughout the three-month follow-up period. Conjunctival injection and
follicular conjunctivitis were the side effects of topical interferon alpha 2b and were
treated with lubrication and steroids.
Conclusion: This case series demonstrated the potential efficacy of interferon alpha 2b
in the treatment of refractory diabetic macular edema. It might be an option in patients
with contraindications for intravitreal injections.
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Diabetic macular edema (DME) is one of the most
common causes of visual loss in the working-age
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population and can occur at any stage of diabetic
retinopathy.[1] The prevalence of DME in patients
with diabetic retinopathy is 2.7–11%, depending on
the type and duration of diabetes.[2–6]
The development of intraocular anti-vascular
endothelial growth factor (anti-VEGF) drugs has
revolutionized the treatment of DME in recent
years and has widely replaced macular laser
photocoagulation (MPC); however, the response
to anti-VEGF therapy can be incomplete in some
patients with DME despite multiple injections.[7]
Both animal and human clinical studies have
demonstrated the importance of inflammatory
processes in the pathogenesis of DME. Various
cytokines and chemokines, including IL-6, IL-8,
tumor necrosis factor-alpha (TNF-α), nuclear factor
kappa-light-chain-enhancer of activated B cells,
protein kinase C, monocyte chemotactic protein,
and nitric oxide synthase in addition to VEGF are
all key components to this pathogenesis.[8, 9]
Interferons, a large group of glycoproteins,
act against VEGF and other cytokines such as
IL-8, IL-10, tissue growth factor beta (TGF-β), and
TNF-α through inhibiting their production.[10]
Moreover, they enhance the barrier function
of retinal microvasculature leading to a more
unassailable retinal structure.[11] Interferon alpha
has an important role in the treatment of various
types of vision-threatening uveitis.[12] Recently,
topical interferon alpha 2b (INF-α2b) has been
successfully employed in the treatment of
refractory pseudophakic macular edema.[13]
Moreover, sub-tenon injection of interferon alpha
2a (INF-α2a) has been effectively utilized in
DME.[14]
In this case series, topical INF-α2b was
investigated for the treatment of refractory DME.
METHODS
This study was a retrospective interventional
case series. All eyes were resistant to multiple
intravitreal anti-VEGF injections and MPC. The
experimental topical INF-α2b treatment was
discussed with the patients and a written
informed consent was obtained. Our compounding
pharmacy prepared the topical drops by adding
two milliliter of distilled water to one milliliter of
INF-α2b in a three MIU vials (3 MIU/ml) (PDferon
3 MIU, Pooyesh Pharmaceuticals, Tehran, Iran).
Treatment of topical INF-α2b began with the initial
regimen of one drop four times per day for the first
two or three months based on the investigators’
clinical judgment, including patient’s symptoms,
subjective visual improvement, best-corrected
visual acuity (BCVA) improvement, ocular surface
health, patient’s tolerability of the regimen and
the improvement in retinal structure and contour
compared to the baseline evaluation and optical
coherence tomography (OCT) findings at the
one-month follow-up visit. The drops were then
tapered by one drop every two or three months
thereafter (Table 1).
RESULTS
Case 1. A 70-year-old male with a history of
type 2 diabetes and hypertension for 16 years
presented with severe non-proliferative diabetic
retinopathy (NPDR) and DME in November 2007.
During his follow-up visits from 2007 to 2018, he
received multiple intravitreal injections including
bevacizumab, combination of bevacizumab and
dexamethasone, combination of bevacizumab and
triamcinolone, ranibizumab, and aflibercept in both
of his eyes. Additionally, MPC was employed in
both eyes and pars plana vitrectomy was used
to treat the DME in his left eye. All of these
treatment modalities failed (Figure 1A) and his
vision decreased to 20/100 and 20/200 from 20/40
and 20/20 in his right and left eye, respectively.
After discussing possible treatment options, he
agreed to start a topical INF-α2b treatment. During
the one-month follow-up visit, his vision improved
by one line (to reach 20/80 and 20/100 in the
right and left eye, respectively) and OCT showed
a significant improvement in macular thickness
(Figure 1B). During the three-month follow-up visit,
both the visual acuity and the OCT findings were
stable (Figure 1C). The patient developed follicular
conjunctivitis one and a half months after the
treatment initiation with the side effects responding
to lubricants and low potency steroids. Tapering of
the study medication began at eight weeks.
Case 2. A 71-year-old male with a history
of type 2 diabetes for 13 years, severe NPDR,
and DME in his both eyes was presented to us
in February 2013. He had undergone cataract
surgery in both eyes before presentation and visual
acuity was measured at 20/40 in both eyes. For
the treatment of DME, he received intravitreal
bevacizumab, combination of bevacizumab and
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Figure 1. (A) Shows the optical coherence tomography (OCT) raster horizontal line passing through the center of the macula in
right (upper left) and left eye (upper right) before starting topical interferon alpha 2b treatment . (B) and (C) are OCTs at one- and
three-month follow-up visits, respectively, in the right (left picture) and left (right picture) eyes. In this case, tapering of the drop
was started at eight weeks.
Figure 2. (A) Demonstrates the optical coherence tomography (OCT) before initiating the topical interferon alpha 2b treatment.
The upper left and upper right are the horizontal raster of the right eye and vertical raster of the left eye, respectively, following
the center of the fovea. (B) and (C) show the OCT at one- and three-month follow-up visits. In this case, tapering of the drop was
started at eight weeks.
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Figure 3. (A) The optical coherence tomography (OCT) depicts a significant diabetic macular edema before starting the topical
interferon alpha 2b in the right eye. (B) The upper picture is the OCT at one-month follow-up visit and indicates a significant
improvement; however, this improvement is suboptimal. The lower OCT picture shows the acceptable response one month later
(two months after the treatment). The diagram shows the thickness changes between the one- and two-month follow-up visits.
(C) Shows the stability of the OCT at three-month follow-up visit. In this case, tapering of the drop was started at 12 weeks.
triamcinolone, and aflibercept injections in his both
eyes. MPC was also utilized in both eyes. During
his follow-up visits, he developed rhegmatogenous
retinal detachment (RRD) in his left eye and
underwent pars plana vitrectomy and silicone oil
injection. The silicone oil was removed three
months after the primary operation. This individual
later developed proliferative diabetic retinopathy
(PDR), and panretinal photocoagulation (PRP) was
implemented for the treatment of PDR in both eyes.
As DME was unresponsive to the aforementioned
treatment modalities and other options such as
ranibizumab and brolucizumab were not available
due to his financial concerns, he was started
on topical INF-α2b after discussing the risks
and benefits of the treatment. Before treatment
initiation, his visual acuity was 20/100 and 20/80
in the right and left eyes, respectively. Figure 2A
demonstrates the OCT findings before starting the
treatment. Figures 2B and 2C show the changes in
the OCT during the one- and three-month follow-
up visits, respectively. At the three-month visit, the
visual acuity was 20/100 and 20/60 in the right
and left eye, respectively. We started to taper the
medication at eight weeks.
Case 3. A 64-year-old female with type 2
diabetes and hypertension for 18 years was
presented to our clinic. At presentation, in June
2010, she was diagnosed with high-risk PDR and
DME in both eyes. She was treated with PRP. She
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Table 1. Treatment protocol
Treatment protocol Duration of the treatment
Four times a day Eight to twelve weeks based on the clinical judgment and the optical coherence tomography
findings at one-month follow-up visit.
Three times a day Eight weeks
Two times a day Eight weeks
One time a day Eight weeks
One time every other day Eight weeks
also received multiple intravitreal bevacizumab,
combination of bevacizumab and triamcinolone,
and aflibercept injections.While the PDR regressed
with PRP, the DME in her right eye was resistant
to all aforementioned injections. MPC was also
performed and was unsuccessful in treating the
DME in this eye (Figure 3A). At this point, her
vision was 20/100 in the right eye. She agreed to
start topical INF-α2b after discussing all treatment
options. During her one-month follow-up visit,
impressive improvement was observed in the OCT
findings (Figure 3B). The visual acuity in the right
eye improved by one line. Both visual acuity
and OCT findings were stable at the three-month
follow-up visit (Figure 3C). As the response to
treatment was not complete at one month, the
initial treatment was continued for three months
when the medication was eventually tapered.
DISCUSSION
Diabetic macular edema is a major complication
of diabetic retinopathy and one of the leading
causes of visual impairment in the working-age
population.[1] Inflammation has an important role
in the pathogenesis of diabetic retinopathy and
DME. Systemic and local inflammatory biomarkers
have been proven to have an important role in the
development and progression of DME.[15]
Based on the importance of inflammatory
processes in the pathogenesis of DME, systemic
low-dose infliximab (TNF-α inhibitor) was employed
in the treatment of the late-stage vision-threatening
refractory DME with promising results.[16] INF-α
might be effective in the treatment of DME due
to its opposite effects on TNF-α.[12] This means
that an increase in concentration of INF-α in
a viable microenvironment can decrease the
production and concentration of TNF-α and vice
versa. Moreover, INF-α has both anti-inflammatory
and anti-proliferative properties. It inhibits the
production of VEGF in addition to IL-8 and TNF- α,
two major local cytokines in the development of
DME.[8–12, 14–16] The sub-tenon injection of INF-α2a
was demonstrated to be effective in the treatment
of refractory DME[14]; however, to the best of
our knowledge, topical INF-α2b has not been
previously employed in the treatment of DME.
Despite being a large molecule, its adequate
penetration through the sclera and cornea has
been demonstrated in previous studies.[13, 14, 17] The
safety of topical use of INF-α2b has also been
shown in previous studies and no major systemic
or local side effects have been reported in the
treatment of patients with ocular surface tumors
with the same dose.[13]
In the three patients in this series, all of the
commonly used treatment modalities either failed
due to ineffectiveness or were too expensive
for the patients. These patients were finally
started on topical INF-α2b four times a day with
the anticipation that based on the importance
of inflammatory processes in the development
and progression of DME, this treatment would
be effective. The treatment plan was continued
for eight to twelve weeks based on the clinical
judgment and OCT findings. The treatment dose
was tapered by one drop every eight weeks
based upon established ocular inflammatory
disease therapies and our successful experience
of employing topical INF-α2b in the treatment of
refractory cystoid macular edema (CME).[13]
In these presented cases, topical INF-α2b was
started when the effects of previous therapies such
as intravitreal injections and MPC were proven
futile and the patients needed further intervention.
Comparison ofOCT findings before and one-month
after the treatment demonstrated an impressive
improvement inmacular structures and thickness in
all cases. These findings were stable or improved
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at the three-month follow-up visit. Conjunctival
injection and follicular conjunctivitis were the
observed side effects and were treated with
lubricants and low potency steroids.
In conclusion, this case series demonstrates
the effectiveness of topical interferon-α2b in
the treatment of selected cases of refractory
DME. This therapy might also be an option
in selected patients who develop complications
after intravitreal injections or in patients who
have contraindications to intravitreal injections.
However, more robust studies such as randomized
clinical trials are required to support our findings.
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